SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience.

Authors

Akash Kataruka
Xiaowen Kong
Brian Haymart
Eva Kline-Rogers
Steve AlmanyFollow
Jay Kozlowski
Gregory D. Krol, Henry Ford HealthFollow
Scott Kaatz, Henry Ford HealthFollow
Michael W. McNamara
James B. Froehlich
Geoffrey D. Barnes

Recommended Citation

Kataruka A, Kong X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, McNamara MW, Froehlich JB, and Barnes GD. SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience Vasc Med 2017; 22(3):197-203

Document Type

Article

Publication Date

6-1-2017

Publication Title

Vascular medicine (London, England)

Keywords

Adult, Age Factors, Aged, Anticoagulants, Blood Coagulation, Continental Population Groups, Decision Support Techniques, Drug Monitoring, Female, Humans, International Normalized Ratio, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Risk Factors, Sex Factors, Smoking, Treatment Outcome, Venous Thromboembolism, Warfarin

Abstract

A high SAMe-TT₂R₂ score predicted poor warfarin control and adverse events among atrial fibrillation patients. However, the SAMe-TT₂R₂ score has not been well validated in venous thromboembolism (VTE) patients. A cohort of 1943 warfarin-treated patients with acute VTE was analyzed to correlate the SAMe-TT₂R₂ score with time in therapeutic range (TTR) and clinical adverse events. A TTR <60% was more frequent among patients with a high (>2) versus low (0-1) SAMe-TT₂R₂ score (63.4% vs 52.3%, p<0.0001). A high SAMe-TT₂R₂ score (>2) correlated with increased overall adverse events (7.9 vs 4.5 overall adverse events/100 patient years, p=0.002), driven primarily by increased recurrent VTE rates (4.2 vs 1.5 recurrent VTE/100 patient years, p=0.0003). The SAMe-TT₂R₂ score had a modest predictive ability for international normalized ratio (INR) quality and adverse clinical events among warfarin-treated VTE patients. The utility of the SAMe-TT₂R₂ score to guide clinical decision-making remains to be investigated.

Medical Subject Headings

Adult; Age Factors; Aged; Anticoagulants; Blood Coagulation; Continental Population Groups; Decision Support Techniques; Drug Monitoring; Female; Humans; International Normalized Ratio; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Treatment Outcome; Venous Thromboembolism; Warfarin

PubMed ID

28145152

Volume

22

Issue

3

First Page

197

Last Page

203